@article{oai:repo.qst.go.jp:00080849,
 author = {Yoshinaga, Keiichiro and Abe, Takashige and Okamoto, Shozo and Uchiyama, Yuko and Manabe, Osamu and M. Ito, Yoichi and Tamura, Naomi and Ito, Natsue and Yoshioka, Naho and Washino, Komei and Shinohara, Nobuo and Tamaki, Nagara and Shiga, Tohru and Keiichiro, Yoshinaga and Natsue, Ito and Naho, Yoshioka and Komei, Washino},
 issue = {1},
 journal = {The Journal of Nuclear Medicine},
 month = {Oct},
 note = {131I-meta-iodobenzylguanidine (131I-MIBG) radiotherapy has shown some survival benefits in metastatic neuroendocrine tumors (NETs). European Association of Nuclear Medicine (EANM) clinical guidelines for 131I-MIBG radiotherapy suggest a repeated treatment protocol, although none currently exists. The existing single-high-dose 131I-MIBG radiotherapy (444 MBq/kg) has been shown to have some benefits for patients with metastatic NETs. However, this protocol increases adverse effects and it requires alternative therapeutic approaches. Therefore, the aim of this study was to evaluate the effects of repeated 131I-MIBG therapy on tumor size and tumor metabolic response in patients with metastatic NETs.},
 pages = {685--694},
 title = {Effects of Repeated 131I-meta-iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activities in Patients with Metastatic Neuroendocrine Tumors},
 volume = {62},
 year = {2020}
}